Intellia Therapeutics, Inc.
NTLA
$23.72
$0.120.51%
| Weiss Ratings | NTLA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | NTLA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Very Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | NTLA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.49 | |||
| Price History | NTLA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -3.44% | |||
| 30-Day Total Return | -24.56% | |||
| 60-Day Total Return | -12.85% | |||
| 90-Day Total Return | -32.55% | |||
| Year to Date Total Return | -32.64% | |||
| 1-Year Total Return | -42.70% | |||
| 2-Year Total Return | -58.36% | |||
| 3-Year Total Return | -75.52% | |||
| 5-Year Total Return | 21.83% | |||
| 52-Week High % Change | -57.83% | |||
| 52-Week Low % Change | 1.93% | |||
| Price | NTLA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $47.48 | |||
| 52-Week Low Price | $20.78 | |||
| 52-Week Low Price (Date) | Apr 19, 2024 | |||
| 52-Week High Price (Date) | Jun 14, 2023 | |||
| Valuation | NTLA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 2.08B | |||
| Enterprise Value | 1.18B | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -5.42 | |||
| Earnings Per Share Growth | -12.34% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 53.79 | |||
| Price/Book (Q) | 1.91 | |||
| Enterprise Value/Revenue (TTM) | 28.50 | |||
| Price | $20.76 | |||
| Enterprise Value/EBITDA (TTM) | -2.04 | |||
| Enterprise Value/EBIT | -2.01 | |||
| Market Cap Category | Mid Cap | |||
| Dividends and Shares | NTLA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 90.46M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | NTLA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 857 285 6200 | |||
| Address | 40 Erie Street Cambridge, MA 02139 | |||
| Website | www.intelliatx.com | |||
| Country | United States | |||
| Year Founded | 2014 | |||
| Profitability | NTLA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -1,420.51% | |||
| Profit Margin | -1,326.51% | |||
| Management Effectiveness | NTLA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -22.83% | |||
| Return on Equity | -- | |||
| Income Statement | NTLA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 36.28M | |||
| Total Revenue (TTM) | 36.28M | |||
| Revenue Per Share | $0.40 | |||
| Gross Profit (TTM) | -398.79M | |||
| EBITDA (TTM) | -506.32M | |||
| EBIT (TTM) | -515.29M | |||
| Net Income (TTM) | -481.19M | |||
| Net Income Avl. to Common (TTM) | -481.19M | |||
| Total Revenue Growth (Q YOY) | -114.12% | |||
| Earnings Growth (Q YOY) | -16.54% | |||
| EPS Diluted (TTM) | -5.42 | |||
| EPS Diluted Growth (Q YOY) | -4.64% | |||
| Balance Sheet | NTLA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 912.22M | |||
| Cash Per Share (Q) | $10.08 | |||
| Total Current Assets (Q) | 998.33M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 1.05B | |||
| Current Ratio (Q) | 8.665 | |||
| Book Value Per Share (Q) | $11.29 | |||
| Total Assets (Q) | 1.30B | |||
| Total Current Liabilities (Q) | 115.21M | |||
| Total Debt (Q) | 115.35M | |||
| Total Liabilities (Q) | 250.81M | |||
| Total Common Equity (Q) | 1.05B | |||
| Cash Flow | NTLA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -31.35M | |||
| Cash from Financing (TTM) | 130.32M | |||
| Net Change in Cash (TTM) | -295.11M | |||
| Levered Free Cash Flow (TTM) | -268.21M | |||
| Cash from Operations (TTM) | -394.09M | |||
